insulin human

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Insuman. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman.

This EPAR was last updated on 01/09/2022

Authorisation details

Product details
Agency product number
Active substance
insulin human
International non-proprietary name (INN) or common name
insulin human
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
  • A10AB01
  • A10AC01
Publication details
Marketing-authorisation holder
Sanofi-aventis Deutschland GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
D-65926 Frankfurt am Main

Product information

01/09/2022 Insuman - EMEA/H/C/000201 - IB/0141

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

Assessment history

How useful was this page?

Add your rating
1 rating